Drugs / D029
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05897216 | Jul 2023 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05952219 | Jun 2023 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT05347576 | Apr → May 2022 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05897216 ↗ |
| Route | Oral | “QD, PO” NCT05347576 ↗ |